Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company was founded in 1991 and is headquartered in Wilmington, Delaware. Incyte's main focus is on oncology, inflammation, and autoimmunity. The company's flagship product, Jakafi, is a JAK1/JAK2 inhibitor used to treat myelofibrosis and polycythemia vera. Incyte has a number of other products in development, including itacitinib, a JAK1 inhibitor for the treatment of graft-versus-host disease, and pemigatinib, a FGFR inhibitor for the treatment of cholangiocarcinoma.